Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak
Detection Principle
ImmunoAssay-Antibody
Target
IgG, IgM vs N
Testing Method
in house ELISA
Testing Method - Additional Info
In-house anti-SARS-CoV-2 IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 nucleocapsid protein (NP) as antigen
Reported Performance
sensitivity: 92.5% (IgG ELISA), 70.8% (IgM ELISA)
Sample Size
226 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements